{"disease":{"id":"abemaciclib","name":"abemaciclib"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05598788","title":"Microsampling Approach for Monitoring of Kinase Inhibitor Targeted Therapies","phase":"","overall_status":"UNKNOWN","enrollment_count":360,"lead_sponsor_name":"Rennes University Hospital","has_results":false},{"nct_id":"NCT07190443","title":"Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":290,"lead_sponsor_name":"Japanese Foundation for Cancer Research","has_results":false},{"nct_id":"NCT06621459","title":"Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"University Hospital, Brest","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}